Actively Recruiting
Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Led by Assiut University · Updated on 2025-03-20
30
Participants Needed
2
Research Sites
266 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
the cyclosporine showed efficacy in many immune cytopenic diseases in the light of numerous case reports and retrospective data. This study compares cyclosporin versus rituximab in steroid-refractory anemia.
CONDITIONS
Official Title
Second-line Treatment of Primary Autoimmune Hemolytic Anemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged more than 18 years old of any sex with a diagnosis of primary warm autoimmune hemolytic anemia confirmed by hemolytic anemia and positive direct antiglobulin test
- Patients who have disease progression or failure after steroid therapy, or who are intolerant to steroids, or who refuse standard treatment
- No evidence of lymphoproliferative malignancy or other autoimmune-related underlying conditions
You will not qualify if you...
- Any contraindications to the study drugs
- Any identified secondary cause of autoimmune hemolytic anemia
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Assiut university hospital
Asyut, Asyut Governorate, Egypt, 17111
Active, Not Recruiting
2
Assiut university hospital
Asyut, Asyut Governorate, Egypt
Actively Recruiting
Research Team
G
ghada Abdallah
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here